Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy. These ITT data were presented today in two late breaker oral presentations at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C.

Results showed that, on an ITT basis,

  • Approximately 25-33% lost 10% or more of their body weight and 12-16% lost at least 15%; and
  • Obese patients on Contrave demonstrated significant improvements in important markers of cardiometabolic risk including waist circumference, HDL and triglycerides

"The data presented today and on Saturday provide a deeper view of Contrave, and what we believe is a balanced efficacy and safety profile," said Eduardo Dunayevich, M.D., Chief Medical Officer of Orexigen. "These findings should help clinicians assess the potential value of Contrave pharmacotherapy in managing obesity and support our belief that if approved, Contrave could meet the broad range of needs of this patient population by virtue of its efficacy, safety and benefits on key markers of cardiometabolic risk."

Additional data from today's late breaker presentations are outlined in the below table:

    Efficacy Result(+)
                                    COR-I                       COR-II
    --------------------------------------------------------------------------
                               PBO 
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The global mHealth market ... by 2020, growing at a CAGR of 47.6% from ... Grand View Research, Inc. Monitoring services is expected to ... to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... incidences of chronic diseases such as cancer, heart ailments, ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
(Date:8/27/2015)... 27, 2015 Biosimilars are not generics ... U.S. Food and Drug Administration (FDA) for recognizing ... its draft guidance issued today. The FDA,s draft ... distinguishable names, calling for biological products to bear ... This proposal reflects the agency,s thinking that "there ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Calif., Oct. 27 Patient Safety Technologies, Inc. (the ... Dreyer as Vice President and Chief Financial Officer.  Mr. ... reporting requirements for the Company and its wholly-owned operating ... role in various strategic initiatives and operational improvements. ...
... in collaboration with the Philadelphia Eagles, today announced that ... Students Run Philly Style, Twilight Wish Foundation and The ... company,s ongoing commitment to supporting local organizations in the ... being awarded these grants in recognition of going above ...
Cached Medicine Technology:Patient Safety Technologies Appoints New Chief Financial Officer 2Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations 2Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations 3Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations 4Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations 5
(Date:8/29/2015)... ... August 29, 2015 , ... People ... pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire smoke ... attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... ... ... An online provider of CPAP machines, masks, supplies, and accessories, My Cpap ... by offering shipping at no cost to you, directly to your door on all ... My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is a ...
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... and Best Practices for Compliance, **Presented by FDAnews and GessNet**, Oct. 14-15, ... internationally renowned expert Fubin Wu, has been specifically designed to provide devicemakers ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... BOULDER, Colo., July 31 Encision Inc. (Amex:,ECI), a ... as a standard of care in minimally-invasive surgery, reported ... 2008., Net sales for the first quarter of ... totaled $3.09 million, representing a 16%,increase over net sales ...
... Nutraceutical,International Corporation (Nasdaq: NUTR ) today reported results ... Net sales for the fiscal,2008 third quarter were $40.5 ... fiscal 2007. For the third quarter of fiscal 2008, ... share, compared to,net income of $2.9 million, or $0.25 ...
... MOUNTAIN VIEW, Calif., July 31 Cardiva Medical, Inc., ... Lien,Chairman and CEO, will present at the BMO Capital ... at 1:15 p.m. EDT at the,Millennium Broadway Hotel in ... of the Company,s current operations and growth,strategy., ...
... new tool in their arsenal in their quest for gold. The team ... in Wellpride Omega-3 Fish Oil for Horses® and Omega-Cure™ for humans, provided ... ... Venice, FL (PRWEB) July 31, 2008 -- The U.S. Olympic eventing squad ...
... globe will be celebrating 30 years of putting patients first at ... , ... (PRWEB) July 31, 2008 -- Planetree Inc. will ... defined it at its annual conference in Chicago this year with ...
... WASHINGTON, July 30 The U.S. House of,Representatives ... that,would grant the U.S. Food and Drug Administration ... crack down on tobacco,marketing and sales to kids. ... bipartisan support. The bill now goes to the ...
Cached Medicine News:Health News:Encision Reports First Fiscal Quarter Results 2Health News:Encision Reports First Fiscal Quarter Results 3Health News:Encision Reports First Fiscal Quarter Results 4Health News:Nutraceutical Reports Q3 Results 2Health News:Nutraceutical Reports Q3 Results 3Health News:Nutraceutical Reports Q3 Results 4Health News:Nutraceutical Reports Q3 Results 5Health News:Nutraceutical Reports Q3 Results 6Health News:Cardiva Medical Announces Presentation at BMO Capital Markets 2008 Focus on Healthcare Conference 2Health News:Fish Oil Fueling Equine Olympians 2Health News:Fish Oil Fueling Equine Olympians 3Health News:Healthcare Leaders Focus on Patient-Centered Care at Annual Planetree Conference 2Health News:Healthcare Leaders Focus on Patient-Centered Care at Annual Planetree Conference 3Health News:House Passes Historic Bill to Protect Kids from Tobacco; Senators Bond & McCaskill Should Cosponsor Legislation 2
Slender 4.5 mm long rounded platform. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish....
Round solid lower plate. Open upper plate with inside diameter 15 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: